Teva Pharmaceutical said it welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia, a biosimilar to Lucentis (ranibizumab).
Cognition Therapeutics announced that its Investigational New Drug (IND) application has been cleared by the FDA for the investigation of CT1812 in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).
Apellis Pharmaceuticals announced that the company has submitted a new drug application (NDA) to the FDA for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to AMD.
Aviceda Therapeutics has submitted an investigational new drug (IND) application to the FDA, supporting the use of its lead intravitreal ocular asset, AVD-104, for the treatment of GA secondary to AMD.
Vision Expo East 2022 will take place in-person from March 31–April 3 at the Jacob Javits Center in New York City.